Testing a new immunotherapy for chronic kidney transplant rejection
Treatments studied
Part of Immune system & allergy, Kidney & urinary clinical trials.
This study tests a new treatment called BiTE (a type of immunotherapy that helps your immune cells attack harmful antibodies) for people whose transplanted kidney is being damaged by chronic active antibody-mediated rejection. The goal is to see if it can safely slow or stop this damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- Your kidney transplant must have been working for at least 6 months.
- Your kidney function (eGFR) must be 20 or higher.
- You must have certain antibodies targeting your donor kidney (called DSA).
- You must have a kidney biopsy showing chronic active antibody-mediated rejection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at certain immune cells (B cells) in the blood and kidney to better understand antibody-mediated rejection in kidney transplant patients. It might help doctors find new ways to diagnose or treat this type of rejection.
This trial tests a new drug called a BiTE (a type of immunotherapy) to lower very high antibody levels in people waiting for a kidney transplant. If successful, it might help you become eligible for a transplant sooner.
This study tests a new combination of drugs (an antibody called CD38 mAb plus azathioprine) to treat a type of chronic rejection that can happen months or years after a kidney transplant. The goal is to see if it can help stabilize or improve kidney function and prevent further damage.
This trial tests whether belatacept can help prevent damage in kidney transplant recipients who develop new antibodies against their donor kidney. It is for people whose kidney function is still stable, which may allow treatment to slow or stop antibody-related injury.
This study looks at tissue samples from kidney transplant patients who have a specific type of long-term rejection called chronic active humoral rejection (cAMR). It aims to better understand the condition and help future patients.
This study tests an experimental drug called CID-103 to treat antibody-mediated rejection (ABMR), a type of immune response that damages transplanted kidneys. The drug targets immune cells that attack the transplant, and researchers hope it may help preserve kidney function and prevent transplant failure.
Hear when a new Antibody Mediated Rejection After Kidney Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.